Immuneering News

Buy Rating Affirmed for Immuneering With $8 Price Target Amidst Promising Pipeline and Upcoming Data Events

TipRanksMay 16 03:35

Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)

TipRanksMay 13 06:55

Immuneering Reports Q1 Results

Seeking AlphaMay 8 09:50

Immuneering Price Target Maintained With a $15.00/Share by Needham

Immuneering Price Target Maintained With a $15.00/Share by Needham

Dow JonesMay 8 05:08

Buy Rating Maintained for Immuneering Amid Promising Clinical Pipeline Developments

TipRanksMay 8 04:25

Immuneering Q1 EPS $(0.49) Misses $(0.46) Estimate

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 3.92 percent increase over losses of $(0.51)

BenzingaMay 7 16:02

Immuneering | 10-Q: Quarterly report

Futu NewsMay 7 15:11 · Announcements

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Preclinical Data Presented at AACR Demonstrating that IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models.

Stockhouse May 7 15:05

Buy Rating Affirmed: Immuneering's Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism

TipRanksMay 2 02:25

Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.

Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.

Zhitong FinanceApr 12 05:40

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $15 price target.

Analyst UpgradesApr 12 05:33

Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)

TipRanksApr 12 05:30

Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors

Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor

BenzingaApr 9 11:04

IMM-1-104 Is Synergistic With Chemotherapy in Pancreatic Cancer Models

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

GlobeNewswireApr 9 11:00

Immuneering(IMRX.US) 10% Shareholder Sells US$1.16 Million in Common Stock

$Immuneering(IMRX.US)$ 10% Shareholder Cormorant Asset Management, LP sold 400K shares of Common Stock on Apr 1, 2024 at an average price of $2.9 for a total value of $1.16 million. This transaction i

Futu NewsApr 3 17:17

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

PDF Version CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF

ImmuneeringApr 2 23:00

Immuneering Is Maintained at Buy by Mizuho

Immuneering Is Maintained at Buy by Mizuho

Dow JonesApr 2 07:01

Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho

Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho

Dow JonesApr 2 07:01

Immuneering Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 190.91% Mizuho $20 → $8 Maintains Buy 03/15/2024 9.09% Jefferies $16 → $3 Downgrades Buy → Hold

BenzingaApr 2 06:49

Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence

TipRanksMar 29 03:26